WO2014091263A1 - Composition pharmaceutique contenant du telmisartan - Google Patents
Composition pharmaceutique contenant du telmisartan Download PDFInfo
- Publication number
- WO2014091263A1 WO2014091263A1 PCT/HU2013/000120 HU2013000120W WO2014091263A1 WO 2014091263 A1 WO2014091263 A1 WO 2014091263A1 HU 2013000120 W HU2013000120 W HU 2013000120W WO 2014091263 A1 WO2014091263 A1 WO 2014091263A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- telmisartan
- weight
- isomalt
- pharmaceutical composition
- sorbitol
- Prior art date
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title claims abstract description 146
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title claims abstract description 83
- 229960005187 telmisartan Drugs 0.000 title claims abstract description 63
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 239000000905 isomalt Substances 0.000 claims abstract description 45
- 235000010439 isomalt Nutrition 0.000 claims abstract description 45
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims abstract description 45
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims abstract description 44
- 239000000243 solution Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 12
- 239000011230 binding agent Substances 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 239000007884 disintegrant Substances 0.000 claims abstract description 9
- 238000005507 spraying Methods 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 48
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 238000005243 fluidization Methods 0.000 abstract description 16
- 238000003825 pressing Methods 0.000 abstract description 5
- 239000000600 sorbitol Substances 0.000 description 44
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 43
- 235000010356 sorbitol Nutrition 0.000 description 43
- 239000000594 mannitol Substances 0.000 description 24
- 229930195725 Mannitol Natural products 0.000 description 23
- 235000010355 mannitol Nutrition 0.000 description 23
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 22
- 229940101564 micardis Drugs 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 14
- 239000000945 filler Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 238000004806 packaging method and process Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 150000005846 sugar alcohols Chemical class 0.000 description 7
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 235000013681 dietary sucrose Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- 239000012752 auxiliary agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229960003194 meglumine Drugs 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- -1 erithritol Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising telmisartan as active ingredient, an alkalizer, a binder, a lubricant and isomaltose and to a process for the preparation thereof.
- telmisartan is an active ingredient useful in the treatment of essential high pressure and also for the prevention of cardiovascular problems /e.g. myocardial attack, stroke/.
- telmisartan in EP 1467712 two layer tablets comprising telmisartan and HCTZ /hydrochlorothiazide/ are disclosed.
- One of the layers contains substantially amorphous telmisartan dissolved in a soluble matrix, while the other layer contains HCTZ in a disintegrating matrix.
- the soluble matrix which contains the telmisartan comprises additionally an alkaline substance, a water soluble filler and optionally further auxiliary agents.
- the alkaline substance may be an alkali hydroxide -e.g. sodium hydroxide or potassium hydroxide -, a basic amino acid -e.g.arginine, lysine - or meglumine.
- suitable water soluble fillers which compensate the low solubility of telmisartan the following substances are mentioned: carbohydrates e.g. monosaccharides such as glucose; oligosaccharides such as saccharose, anhydrous lactose and lactose monohydrate; sugar alcohols e.g. sorbitol, mannitol, dulcitol, rhibitol and xylitol. Stress is laid on the importance of sorbitol as a particularly preferable representative of the water soluble fillers.
- carbohydrates e.g. monosaccharides such as glucose
- oligosaccharides such as saccharose, anhydrous lactose and lactose monohydrate
- sugar alcohols e.g. sorbitol, mannitol, dulcitol, rhibitol and xylitol. Stress is laid on the importance of sorbitol as a particularly preferable representative of the water soluble fillers.
- suitable hardness relates to a value above 100N, preferably above 130N.
- the inventors referred to EP 1467712 and therefore carried out the experiments with sorbitol as selected sugar alcohol in order to produce tablets of suitable hardness.
- the inventors found it as surprising that the hardness of the tablets depends on the specific surface rather than on the particle size of sorbitol.
- suitable tablets hardness can be achieved with a specific surface of sorbitol of 0.75-3.5 m 2 /g, preferably 1.4-3.0 m 2 /g, particularly preferably 2.0-2.5 m 2 /g.
- telmisartan can be significantly increased and in the place of the expensive and circumstantial powder drying the cheaper and more simple fluidization granulation can be used for the preparation of the telmisartan tablets.
- the following water soluble fillers are enumerated: carbohydrates e.g. glucose; oligosaccharides e.g. sacharose; and sugar alcohols e.g. erithritol, sorbitol, mannitol, dulcitol, sorbitol and xylitol. Stress is laid on mannitol, erythritol, sorbitol and saccharose as particularly suitable water soluble fillers
- telmisartan and HCTZ containing two layer tablets are prepared also by fluidization granulation and hereby a surfactant or emulsifier is used.
- One layer of the tablet contains the telmisartan and the other the HCTZ in a disintegrating matrix.
- telmisartan a tablet comprising telmisartan, sodium hydroxide, PVP, lactose monohydrate, crospovidone, meglumine, magnesium stearate and water is disclosed; the tablet contains no surfactant.
- the two layer tablet set forth in IN 2009/MU02745 comprises no surfactant in the telmisartan containing layer and no disintegrant in the HCTZ containing layer.
- the telmisartan is prepared by a process other than powder drying.
- a telmisartan composition is disclosed which contains neither a surfactant, nor an emulsifier and is prepared by using the cheaper and more simple fluidization granulation in place of the powder drying.
- the following fillers are enumerated: saccharose , lactose, mannitol, xylitol, sorbitol, maltitol, lactitol, erythritol, isomalt and mixtures thereof.
- sorbitol Exemplified are sorbitol, mannitol, saccharose and lactose while sorbitol is mentioned as particularly preferable filler.
- the reason thereof is that -compared to mannitol, saccharose and lactose - the use of sorbitol provides a higher total yield, the composition can be more readily tabletted and the tablets obtained are less brittle.
- telmisartan containing composition crystalline telmisartan is dissolved in the aqueous solution of sodium hydroxide and meglumine, and thereafter Povidon K25 is added to the solution in order to stabilize the amorphous state of telmisartan.
- the solution obtained is subjected to spray-drying in a drying column. This procedure results in the formation of an amorphous telmisartan powder.
- the amorphous telmisartan is homogenized first with sorbitol and thereafter with magnesium stearate and finally pressed into tablets.
- the drawback of the powder drying process is that the apparatus can be used only for this purpose and further equipment is required for the preparation of the product. Additionally the technology is energy intensive and a higher temperature must be used as compared to the fluidization granulation apparatus..
- An object of the invention is the preparation of a telmisartan containing tablet composition which is resistant to the moisture content of the air and is therefore stable for a significantly longer period of time than the sorbitol containing tablets -s.g. Micardis -, and is bioequivalent with the tablets of the originator.
- a further object of the invention is the elaboration of a simple high yield process for the preparation of the above telmisartan containing composition which is cheaper than powder drying.
- Such a less hygroscopic tablet which resists to a higher extent to the moisture content of air can be packaged in a much more simple and cheaper way and this constitutes a further advantage.
- telmisartan containing solution can be used to replace powder drying by spraying the telmisartan containing solution onto the isomalt while omitting the use of a surfactant or an emulsifier;
- the granulate obtained can be more readily pressed into tablets with smaller losses;
- An object of the invention is a pharmaceutical composition
- telmisartan as active ingredient, an alkalizer, a binder, a lubricant and isomalt.
- the composition is free from a surfactant, an emulsifier and a disintegrant.
- the composition contains as binder PVP and/or HPMC, preferably PVP.
- the composition contains as lubricant magnesium stearate or sodium stearyl fumarate, preferably magnesium stearate.
- the composition contains 10-20 % by weight, preferably 15-18 % by weight, particularly preferably 16.5 % by weight of telmisartan
- the composition contains 60-86.7 % by weight, preferably 70-80 % by weight, particularly preferably 71 % by weight of isomalt.
- the composition contains 10-20 % by weight, preferably 15-18 % by weight, particularly preferably 16.5 % by weight of telmisartan and 60-86.7 % by weight, preferably 70- 80 % by weight, particularly preferably 71 % by weight of isomalt.
- a process for the preparation of a pharmaceutical composition which comprises dissolving the
- telmisartan in the aqueous solution of the alkalizers, adding the solution of the binder, thereafter spraying the solution thus obtained onto the isomalt in a fluidization apparatus, homogenizing the granulate thus obtained with the lubricant and finally pressing the homogenized product into tablets.
- neither a surfactant, nor an emulsifier not a disintegrant is used.
- a surfactant nor an emulsifier not a disintegrant.
- mannitol By way of experiment we have sprayed the telmisartan containing solution onto a mannitol containing fluid bed. We have chosen mannitol because this is a sugar alcohol chemically strictly related to sorbitol, it is considerably less water soluble and therefore it could be expected that mannitol would not be dissolved during granulation.
- composition of the product thus obtained is as follows:
- mannitol When using mannitol the problems occurring in the application of sorbitol did not take place i.e. mannitol was not dissolved in the granulating liquid even in case of a higher spraying speed of 7.2-7.8 g/min and the granulate particles formed did not stick together. However we have observed sticking or adhesion which made the tableting procedure more difficult and moreover a large number of waste tablets was formed. For this reason we have rejected the industrial scale use of mannitol.
- microcrystalline cellulose as water insoluble auxiliary agent.
- the fluidization granulation was successful, however the in vitro dissolution of the telmisartan composition prepared by using microcrystalline cellulose was very different from that of Micardis. Since due to this deviation the registration requirements relating to bioequivalence could not be fulfilled, we had to reject this solution as well.
- the fluidization granulation of the telmisartan containing composition can be carried out by using a high spraying speed of 7.2-7.8 g min. even in the absence of a surfactant or an emulsifier.
- the granules formed can be pressed to tablets in a significantly safer manner.
- the easier tabletting manifests itself in two important respects.
- a smaller number of waste tablets is formed; the yield of the isomalt technology is higher by 15 % than that of the mannitol procedure.
- the surface of the tablets obtained by the isomalt procedure is more shining and no lubrication error occurs as happened in case of the mannitol containing tablets.
- Isomalt is a disaccharide belonging into the group sugar alcohols and consisting of gluccopyranosyl-sorbitol /GPS/ and glucopyranosyl-mannitol /GPM .
- the GPS:GPM ratio is 1 :1 .
- Isomalt is a sugar alcohol of outstanding morphology, it consists of amorphous particles, is not polymorph, accordingly polymorph transformation is not to be feared with the progress of time.
- the large specific surface of the amorphous particles guarantees a homogenous admixture of the active ingredient and the other active ingredients and no subsequent segregation takes place.
- a further advantage resides in the fact that when using isomalt in the preparation of the telmisartan composition a disintegrant can be omitted because the tablets obtained possess outstanding dissolution and disintegration properties, If no disintegrant is used the composition of the tablet is more simple, the preparation of the tablets is more economical, better and also the load of the human organism by superfluous inactive synthetic substances is decreased.
- the inorganic base content of the invention composition amounts to 1-2 % by weight, preferably 1.3-1.7 % by weight and particularly preferably 1.5 % by weight.
- the organic base content of our composition is 1-10 % by weight preferably 4-8 % by weight and particularly preferably 5 % by weight.
- the binder content of the our composition is 1-10 % by weight, preferably 4-8 % by weight and particularly preferably 5 % by weight.
- the lubricant content of our composition is 0.3-2.0 % by weight, preferably 0.8-1.5 % by weight, particularly preferably 1 % by weight.
- test conditions were as follows: The compositions were allowed to stand in Petri dishes, at 40°C and a relative moisture content of 75 % by weight for 4 weeks, in accordance with the Directive ICH Q1A R2/.
- the percental water uptake of the Micardis composition is identical with that of sorbitol /31-32 %/ within the margin of error. Additionally since sorbitol is a high hygroscopic substance, the Micardis composition absorbs a large amount of water from the air. This is the reason why the Micardis compositions are put on the market in a three layer /OPA/PVC/ so-called "cold blister" packaging which protects the tablets from moistening and liquefying due to the effect of the moisture content of the air.
- mannitol does not practically absorb water and the water absorption of the isomalt containing telmisartan compositions of the invention is about 6.5 % i.e. only one- fifth of that of the Micardis compositions.
- the results of the above test are demonstrated in a spectacular manner on Figures 3-5 by showing the condition of sorbitol, isomalt and telmisartan compositions containing sorbitol and isomalt, respectively after 4 weeks of storage.
- Figure 3 shows the condition of GalenIQ800 /isomalt/. It can be seem that under such conditions isomalt keeps its powder form.
- Figure 4 shows the condition of sorbitol. The Figure clearly demonstrates that under the above conditions sorbitol is moistened under the effect of the moisture content of air and is fully liquefied.
- Figure 5 shows the condition of tablets prepared by us containing GalenlQ 800 /isomalt/ and 40 mg of telmisartan in four Petri dishes. The left rear Figure shows the condition of our tablets comprising GalenlQ 800 /isomalt/ and 40 mg of telmisartan.
- the left front Figure presents the condition of the tablets prepared by us, containing GalenlQ 800 /isomalt/ and 80 mg of telmisartan active ingredient.
- the right rear shows the condition of the Micardis tablets containing sorbitol and 40 mg of telmisartan active ingredient; while the right front Figure shows the condition of Micardis tablets containing sorbitol and 80 mg of telmisartan.
- Figure 6 presents a comparison of the dissolution /in a phosphate buffer,pH 7.5/ of the Micardis tablet comprising 80 mg of telmisartan and sorbitol with the isomalt containing telmisartan tablet according to the present invention.
- the test conditions were as follows: the dissolving liquid /phosphate buffer/ was stirred with a paddle, at 75 rpm.
- Moisture content not more than 7.0 %
- Active ingredient content 95.0-105.0 %
- compositions meet the requirements
- the three layer Cold blister packaging provides a better protection against the moisture content of the air than the two layer PVC/PVdC packaging;
- the active ingredient content of the mannitol containing tablets decreased with the progress of time in both the Cold blister and the two layer PVC/PVdC packaging, while on the other hand the active ingredient content of the isomalt containing invention tablets did not decrease in said packaging after the storing period of 4 weeks;
- the invention composition shows an in vitro dissolution equivalent with that of the Micardis tablet of the originator.
- the invention composition is not as strongly hygroscopic as the Micardis tablet, therefore our composition remains more stable than the sorbitol containing product for a significantly longer period of time and this enables the substitution of the expensive Cold blister packaging by a much cheaper packaging material, or -alternatively -if Cold blister is used, the shelf-time will lengthen.
- the composition can be prepared in a fluidization granulating equipment generally used in pharmaceutical industry.
- the granulate can be prepared directly after dissolving of the telmisartan and this results in a saving of energy; additionally fluidization is carried out at a lower temperature than powder drying which represents a saving of time since the homogenization step with sorbitol can be omitted.
- fluidization granulation is performed with isomalt as filler -contrary to the use of sorbitol - there is no risk of the in situ dissolving of the isomalt filler. For this reason the telmisartan solution can be sprayed onto the isomalt with a higher spraying speed and this enables a rapid granulating step.
- Fluidization granulation can be carried without using a surfactant and an emulsifier.
- the technology is rendered more simple and the load of the human organism with pharmaceutically inactive excipients is reduced.
- the preparation of the telmisartan composition does not require the use of a disintegrant because the isomalt containing tablets possess outstanding dissolution and disintegrating properties.
- a further advantage of the isomalt containing invention compositions over the tablets containing sorbitol and mannitol is that it can be pressed more readily into tablets, because identical pressing strength provides higher tablet strength and better wear resistance.
- the isomalt containing granules can be more easily pressed and with less losses than the sorbitol and mannitol containing granules and therefore - contrary to the use of sorbitol - there is no need of the use of a special specific surface variant.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une composition pharmaceutique comprenant du telmisartran en tant qu'ingrédient actif, un alcalizeur, un liant, un lubrifiant et de l'isomalt. L'invention concerne également un procédé de préparation des compositions pharmaceutiques précitées qui consiste à dissoudre le telmisartan dans la solution aqueuse des alcalizeurs, puis à ajouter la solution de liant, à pulvériser la solution ainsi obtenue dans un appareil de fluidisation sur l'isomalt, à homogénéiser le granulé ainsi obtenu au moyen du lubrifiant et à presser le produit homogénéisé obtenu en comprimés. Dans cette invention, on n'utilise ni tensioactif, ni émulsifiants ni désintégrant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP1200722 | 2012-12-11 | ||
HUP1200722 | 2012-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014091263A1 true WO2014091263A1 (fr) | 2014-06-19 |
Family
ID=89665947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2013/000120 WO2014091263A1 (fr) | 2012-12-11 | 2013-12-10 | Composition pharmaceutique contenant du telmisartan |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR093922A1 (fr) |
WO (1) | WO2014091263A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017520631A (ja) * | 2014-07-30 | 2017-07-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 経口崩壊性錠剤 |
CN112870174A (zh) * | 2021-02-08 | 2021-06-01 | 天方药业有限公司 | 一种替米沙坦片剂的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009135646A2 (fr) * | 2008-05-05 | 2009-11-12 | Farmaprojects, Sa | Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle |
WO2010137855A2 (fr) * | 2009-05-27 | 2010-12-02 | Dasan Medichem Co., Ltd. | Comprimé multicouches comprenant une couche effervescente |
WO2012055941A1 (fr) * | 2010-10-27 | 2012-05-03 | Krka,Tovarna Zdravil, D. D., Novo Mesto | Composition pharmaceutique multicouche comprenant du telmisartan et de l'amlodipine |
-
2013
- 2013-12-10 WO PCT/HU2013/000120 patent/WO2014091263A1/fr active Application Filing
- 2013-12-11 AR ARP130104632A patent/AR093922A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009135646A2 (fr) * | 2008-05-05 | 2009-11-12 | Farmaprojects, Sa | Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle |
WO2010137855A2 (fr) * | 2009-05-27 | 2010-12-02 | Dasan Medichem Co., Ltd. | Comprimé multicouches comprenant une couche effervescente |
WO2012055941A1 (fr) * | 2010-10-27 | 2012-05-03 | Krka,Tovarna Zdravil, D. D., Novo Mesto | Composition pharmaceutique multicouche comprenant du telmisartan et de l'amlodipine |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017520631A (ja) * | 2014-07-30 | 2017-07-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 経口崩壊性錠剤 |
US9789059B2 (en) | 2014-07-30 | 2017-10-17 | Boehringer Ingelheim International Gmbh | Oral disintegrating tablet |
US10918595B2 (en) | 2014-07-30 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Oral disintegrating tablet |
CN112870174A (zh) * | 2021-02-08 | 2021-06-01 | 天方药业有限公司 | 一种替米沙坦片剂的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AR093922A1 (es) | 2015-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10064826B2 (en) | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process | |
EP1916994B1 (fr) | Preparation de compositions pharmaceutiques de medicaments insolubles a l'eau a diffusion rapide et compositions pharmaceutiques ainsi preparees | |
JP5209966B2 (ja) | 崩壊性の改善された医薬組成物の製造方法 | |
CN104661649A (zh) | 包含替格瑞洛的固态口服医药制剂 | |
JP6399115B2 (ja) | アンギオテンシンii拮抗作用を有する化合物を含有する固形医薬組成物 | |
US20190125666A1 (en) | Orally disintegrating tablet | |
WO2013026553A1 (fr) | Composition comprenant de l'edoxaban | |
CA2934832C (fr) | Preparation solide comprenant de la tofogliflozine et procede de production associe | |
PL236001B1 (pl) | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję | |
KR101171375B1 (ko) | 난용성 약물을 함유하는 경구 제형 | |
CA2804358A1 (fr) | Compositions pharmaceutiques contenant de la vanoxerine | |
WO2014091263A1 (fr) | Composition pharmaceutique contenant du telmisartan | |
US20160081937A1 (en) | Tablet with increased drug load of odanacatib | |
JP5823592B2 (ja) | 安定性が改善された製剤 | |
WO2020148219A1 (fr) | Procédé de fabrication de composition pharmaceutique comprenant du néfopam et de l'acétaminophène, et composition pharmaceutique ainsi obtenue | |
KR20180064420A (ko) | 비타민 c 및 아연 정제의 안정 조성물 | |
EP2181705A1 (fr) | Formulation à libération prolongée de gliclazide | |
RU2377989C2 (ru) | Лекарственное средство триметазидина в форме матриксной таблетки с пролонгированным действием и способ его получения | |
JP6552088B2 (ja) | 造粒顆粒およびその製造方法と、錠剤およびその製造方法 | |
US20180344648A1 (en) | Clobazam tablet formulation and process for its preparation | |
CA3048968A1 (fr) | Composition pharmaceutique orale de lurasidone et sa preparation | |
KR102231289B1 (ko) | 고함량 콘드로이틴설페이트 약학 제제 및 이의 제조방법 | |
JP2016222651A (ja) | ミグリトール含有口腔内崩壊錠 | |
JP5801266B2 (ja) | 疎水性薬物を含む錠剤製造方法 | |
EP4374855A1 (fr) | Forme pharmaceutique de dosage de candesartan et d'indapamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13826581 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13826581 Country of ref document: EP Kind code of ref document: A1 |